Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px
Document › Details

Calliditas Therapeutics AB. (11/15/17). "Press Release: Pharmalink Is Renamed Calliditas Therapeutics".

Organisation Organisation Optimum Strategic Communications
Product Product  public relations / investor relations (services)
Index term Index term Calliditas Therapeutics–Optimum Strategic Communications: public relations, 201711 service existent by Optimum
     


The specialty pharmaceutical company Pharmalink AB today announced that it has changed its name to Calliditas Therapeutics AB (“Calliditas Therapeutics” or the “company”).

The Swedish Companies Registration Office has approved and registered the company's change of name from Pharmalink AB to Calliditas Therapeutics AB. More information about Calliditas Therapeutics and its clinical projects can be found on the new website www.calliditas.se.


For further information, please contact:

Calliditas Therapeutics AB
Renée Aguiar-Lucander, Chief Executive Officer
Mobile: +46 (0)72 252 1006
Email: renee.lucander@calliditas.se

Mikael Widell, Head of Communications
Mobile: +46 (0)70 311 9960
Email: mikael.widell@calliditas.se
www.calliditas.se

Optimum Strategic Communications
Mary Clark, Supriya Mathur, Hollie Vile
Email: calliditas@optimumcomms.com
Tel: +44 (0)203 714 1787


Notes to editors


About Calliditas Therapeutics

Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications. Calliditas Therapeutics is focused on the development and commercialization of its lead product candidate, Nefecon, which has successfully completed a Phase 2b clinical study as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. In addition, the company has identified other potential uses of Nefecon in niche indications, and will investigate the development of these to provide new treatments for patients with unmet medical needs.

Visit www.calliditas.se for further information.


Calliditas Therapeutics AB
Wallingatan 26B
SE-111 24 Stockholm
Sweden

Company number: 556659-9766

   
Record changed: 2017-11-26

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px